August 24, 2011
By Erica Teichert
While HPV vaccines are mainly used to protect young women from cervical cancer, the shots have also been found to prevent other types of disease, including penile cancer and genital warts in males. Now, a new study has shown that GlaxoSmithKline’s Cervarix may also prevent anal cancer in women.
The NIH-sponsored study monitored 4,210 female patients inoculated with Cervarix in Costa Rica; after four years, the researchers found the vaccine had prevented 62% of cervical cancers and 77% of anal cancers due to HPV. The vaccine shields patients from two HPV strains–16 and 18–which have been linked to anal cancer, in addition to multiple other strains of the infection.
“We know anal HPV 16, but also 18, cause the bulk of anal cancers. We know if we remove the infection, it will greatly reduce the likelihood for the cancer,” said Dr. Aimee Kreimer from the National Cancer Institute, to Reuters. Kreimer’s study has been published in Lancet Oncology.
The study also found that the vaccine protects against additional HPV types than previously thought, including types 31, 33 and 45, according to Reuters.
Incidence & Mortality
From 2004-2008, the median age at diagnosis for cancer of the anus, anal canal, and anorectum was 60 years of age3X Close
Table I-11 (http://seer.cancer.gov/csr/ 1975_2008/results_single/ sect_01_table.11_2pgs.pdf). Approximately 0.0% were diagnosed under age 20; 1.1% between 20 and 34; 9.4% between 35 and 44; 24.7% between 45 and 54; 25.0% between 55 and 64; 18.0% between 65 and 74; 15.2% between 75 and 84; and 6.6% 85+ years of age.
The age-adjusted incidence rate was 1.6 per 100,000 men and women per year. These rates are based on cases diagnosed in 2004-2008 from 17 SEER geographic areas.
|All Races||1.4 per 100,000 men||1.8 per 100,000 women|
|White||1.5 per 100,000 men||2.0 per 100,000 women|
|Black||1.9 per 100,000 men||1.7 per 100,000 women|
|Asian/Pacific Islander||0.5 per 100,000 men||0.5 per 100,000 women|
|American Indian/Alaska Native a||1.5 per 100,000 women|
|Hispanic b||0.8 per 100,000 men||1.1 per 100,000 women|
From 2004-2008, the median age at death for cancer of the anus, anal canal, and anorectum was 65 years of age4X Close
Table I-13 (http://seer.cancer.gov/csr/ 1975_2008/results_single/ sect_01_table.13_2pgs.pdf). Approximately 0.0% died under age 20; 0.6% between 20 and 34; 6.4% between 35 and 44; 19.5% between 45 and 54; 23.3% between 55 and 64; 19.7% between 65 and 74; 19.7% between 75 and 84; and 10.9% 85+ years of age.
The age-adjusted death rate was 0.2 per 100,000 men and women per year. These rates are based on patients who died in 2004-2008 in the US.
|All Races||0.2 per 100,000 men||0.2 per 100,000 women|
|White||0.2 per 100,000 men||0.2 per 100,000 women|
|Black||0.2 per 100,000 men||0.2 per 100,000 women|
|Asian/Pacific Islander||0.1 per 100,000 women|
|American Indian/Alaska Native a|
|Hispanic b||0.1 per 100,000 men||0.1 per 100,000 women|